Investments
67Portfolio Exits
11Funds
5About BioVentures Investors
BioVentures Investors has three funds currently under management; all focused on the commercial development of advanced technology in Life Sciences and Healthcare. BioVentures currently has over $145 million under management. Investments in individual companies typically range from $3 to $7 million dollars. Fund Partners typically take board seats, or in those transactions in which we do not lead or co-lead, attend all Board meetings as observers.
Want to inform investors similar to BioVentures Investors about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Research containing BioVentures Investors
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned BioVentures Investors in 1 CB Insights research brief, most recently on Apr 23, 2020.
Latest BioVentures Investors News
Dec 10, 2020
BRAINBox Solutions has announced the initial closing on a $23 million Series A financing to support the clinical development of the company's BRAINBox TBI (Traumatic Brain Injury) Test to aid both in the diagnosis and prognosis of mild TBI (concussion). BioVentures Investors led the financing round and was joined by the Tauber Foundation, the Virginia Tech Carilion Innovation and Seed Funds, Genoa VC, Pharmakon Holdings LLC, Astia Angels and additional qualified investors, including Kevin Love, professional basketball player and mental health advocate. BRAINBox Solutions is developing the first AI-enabled, multi-modality approach for the diagnosis and prognosis of Mild Traumatic Brain Injury, commonly referred to as a concussion. The company seeks to establish a clinical best-practice standard for the diagnosis and prognosis of concussion. The product incorporates a panel of proprietary, patented blood biomarkers that can be read in a few moments on a point-of-care instrument or using standard laboratory systems, as well as neurocognitive testing, to provide a single-system score that measures the severity of the injury and guide treatment. The company is led by key physician and scientific thought leaders in the field and an experienced, clinically focused management team. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
BioVentures Investors Investments
67 Investments
BioVentures Investors has made 67 investments. Their latest investment was in PathologyWatch as part of their Series A - II on December 12, 2020.
BioVentures Investors Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
12/17/2020 | Series A - II | PathologyWatch | $2M | Yes | 4 | |
12/2/2020 | Series A | BRAINBox | $23M | Yes | 10 | |
11/12/2019 | Series B | Sonomotion | $10M | No | 7 | |
10/1/2019 | Series D - II | |||||
4/18/2019 | Series A - II |
Date | 12/17/2020 | 12/2/2020 | 11/12/2019 | 10/1/2019 | 4/18/2019 |
|---|---|---|---|---|---|
Round | Series A - II | Series A | Series B | Series D - II | Series A - II |
Company | PathologyWatch | BRAINBox | Sonomotion | ||
Amount | $2M | $23M | $10M | ||
New? | Yes | Yes | No | ||
Co-Investors | |||||
Sources | 4 | 10 | 7 |
BioVentures Investors Portfolio Exits
11 Portfolio Exits
BioVentures Investors has 11 portfolio exits. Their latest portfolio exit was Hydra Biosciences on December 14, 2018.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/14/2018 | Asset Sale | 2 | |||
3/21/2013 | IPO | Public | 2 | ||
12/20/2012 | Acquired | 1 | |||
Date | 12/14/2018 | 3/21/2013 | 12/20/2012 | ||
|---|---|---|---|---|---|
Exit | Asset Sale | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 2 | 2 | 1 |
BioVentures Investors Fund History
5 Fund Histories
BioVentures Investors has 5 funds, including Bioventures Investors Medtech Growth Capital.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
12/15/2020 | Bioventures Investors Medtech Growth Capital | $204.5M | 2 | ||
10/7/2016 | BioVentures Investors IV | ||||
1/1/2007 | BioVentures Investors III LP | ||||
5/31/2003 | BioVentures Investors II LP | ||||
12/31/1999 | BioVentures Investors LP |
Closing Date | 12/15/2020 | 10/7/2016 | 1/1/2007 | 5/31/2003 | 12/31/1999 |
|---|---|---|---|---|---|
Fund | Bioventures Investors Medtech Growth Capital | BioVentures Investors IV | BioVentures Investors III LP | BioVentures Investors II LP | BioVentures Investors LP |
Fund Type | |||||
Status | |||||
Amount | $204.5M | ||||
Sources | 2 |
BioVentures Investors Team
4 Team Members
BioVentures Investors has 4 team members, including current Founder, Managing Partner, Marc E. Goldberg.
Name | Work History | Title | Status |
|---|---|---|---|
Marc E. Goldberg | Founder, Managing Partner | Current | |
Name | Marc E. Goldberg | |||
|---|---|---|---|---|
Work History | ||||
Title | Founder, Managing Partner | |||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.